RBM-007 is a novel oligonucleotide-based aptamer with potent anti-FGF2 activity. Intravitreal administration of RBM-007 in animals demonstrated anti-angiogenic and anti-scarring effects, consistent with a therapeutic effect desired in the treatment of exudative/wet AMD (wet AMD). We have completed phase II clinical trials in long-term anti-VEGF pretreated wet AMD (TOFU study) and treatment-naïve wet AMD (TEMPURA study) early in 2022 in the US. In the TOFU study, RBM-007 alone or in combination with aflibercept did not improve best-corrected visual acuity (BCVA) and central subfield thickness (CST) over aflibercept alone tough the change in BCVA and CST at week 16 (primary endpoint) was very marginal in all the three treatment groups. However, in the TEMPURA study, majority of the subjects showed improvement in BCVA/CST and pronounced effect was demonstrated in a few treatment-naïve subjects. These results indicated that RBM-007 appears effective in treatment naïve compared to pretreated wet AMD, showing an exciting possibility of RBM-007 as a first-in-class therapy for treatment-naïve wet AMD. RBM-007 is also effective to cure Achondroplasia (ACH), the most prevalent genetic form of dwarfism in humans, caused by activating mutation in FGFR3 tyrosine kinase. We will share the recent progress in pre-clinical and clinical developments of ACH with RBM-007.